Search Results for keywords:"drug development"

Search Results: keywords:"drug development"

H. R. 8211 — To amend title 18, United States Code, to prohibit former employees of covered health agencies from serving on the board of entities involved in development and research of a drug, biological product, or device and from profiting from a drug, biological product, or device, and for other purposes.
💰
May 01, 2024
Status:Introduced in House
Congress:118
Words:1,665
H. R. 8211, also known as the “Fixing Administrations Unethical Corrupt Influence Act” or the “FAUCI Act,” aims to prevent former top officials from the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention from...
Simple Explanation
The bill wants to stop important people who used to work for big health agencies from helping companies make medicine or devices right after they leave their jobs, so there is no funny business with money or secret plans. If they break the rules, they could get in big trouble, like paying a lot of money or even going to jail.
S. 4905 — To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
July 31, 2024
Status:Introduced in Senate
Congress:118
Words:2,469
The bill, known as the "Innovation in Pediatric Drugs Act of 2024," aims to update the Federal Food, Drug, and Cosmetic Act to improve the investigation of drugs targeting pediatric cancer. It proposes changes to ensure timely completion of pediatric study requirements and outlines penalties...
Simple Explanation
The bill aims to make it easier and quicker for kids with cancer to get special medicine by making new rules for testing these medicines. It wants to ensure that companies follow these rules and ask people about their opinions to make sure they work well for everyone.
H. R. 7248 — To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
February 06, 2024
Status:Introduced in House
Congress:118
Words:2,101
H.R. 7248, also known as the “FDA Modernization Act 3.0,” aims to amend the Federal Food, Drug, and Cosmetic Act to improve nonclinical testing methods for drugs. The bill's goal is to establish a process for qualifying nonclinical testing methods that reduce or replace the...
Simple Explanation
H.R. 7248 is like a plan to find better ways to test if medicine is safe without using so many animals, making the process quicker and better for everyone.
H. R. 3433 — To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
September 20, 2024
Status:Reported in House
Congress:118
Words:5,960
H. R. 3433, known as the "Give Kids a Chance Act of 2024," aims to amend the Federal Food, Drug, and Cosmetic Act to improve the investigation of drugs for pediatric cancer by requiring specific targeted studies and enhancing FDA authority. It also extends the priority review voucher program...
Simple Explanation
The "Give Kids a Chance Act of 2024" is like making a new rulebook to help find better medicines for kids with cancer, making sure everyone involved works together nicely, and keeping everyone honest about sharing important findings.

Showing 1 to 4 of 4 results